This initial pattern of tau deposition is observed during the preclinical AD stage and is associated with reductions in memory performance (41, 42, 45, 46), raising the possibility that preclinical AD-related memory decline in aging may be partially mediated by changes in neural selectivity. The gene discussed is MAPT; the disease is Alzheimer disease.